Over the past decade, international efforts have greatly increased the number of people in developing countries receiving antiretroviral therapy to treat HIV/AIDS. Today, 17 million people in the developing world are receiving therapy, although nearly 37 million people worldwide are living with HIV.

Our Role

Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine/tenofovir disoproxil fumarate) are recommended by the World Health Organization as components of antiretroviral therapy. We make these medicines available in low- and middle-income countries through two means:

  • We work with regional business partners to provide Viread and Truvada at steeply discounted prices that represent little or no profit to us.
  • We work with generic licensing partners in India, China and South Africa to produce high-quality, low-cost versions of our HIV therapies to sell in developing countries.

Our single tablet regimens Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) were developed and are distributed through joint ventures with Merck and Janssen Therapeutics, respectively. We work with these companies to manage access for developing countries.

Also, as new HIV medicines advance through the research and development pipeline, we take steps to introduce them through access programs. For example, Gilead expanded its Medicines Patent Pool (MPP) licensing agreements by granting generic manufacturers in India, China and South Africa future rights to develop its tenofovir alafenamide (TAF) based regimen, for the treatment of HIV and hepatitis B in 112 resource-limited countries.

Progress to Date 

  • The number of people in developing countries receiving Gilead antiretroviral therapy has increased from fewer than 30,000 in 2006 to 10 million in 2016. Almost two-thirds of the people now treated for HIV in developing world countries receive Gilead medicines.
  • More than 130 countries are included in access efforts, home to nearly 95 percent of people with HIV in the developing world.
  • We work to register our HIV medicines with regulatory authorities in access countries.